SMARCE1P7

Across TCGA pan-cancer cohorts, SMARCE1P7 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated SMARCE1P7 data layer.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SMARCE1P7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SMARCE1P7 expression acts as an unfavorable survival marker, although some lineages such as BRCA show a favorable association.

CESC, STAD, and PAAD are the cancer types where SMARCE1P7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Tertile	III,IV	0.091	0.755	<.001	96	view →
STAD	OS	Tertile	III,IV	0.243	0.656	<.001	27	view →
PAAD	DFS	Tertile	All	0.112	0.504	.025	18	view →
BLCA	DFS	Tertile	All	0.373	0.633	.012	18	view →
BRCA	DFS	Tertile	All	1.000	0.519	.029	12	view →
GBM	DFS	Tertile	All	0.061	0.288	<.001	9	view →
KIRC	DFS	Tertile	III,IV	0.204	0.483	.046	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SMARCE1P7–CESC (OS)

Open the CESC breakdown →